

Environmental and Social Data Sheet¹

Overview

Project Name:	TECHEU VD TISSIUM (IEU TI2)
Project Number:	2025-0618
Country:	France
Project Description:	Tissium is a French medical device company pioneering a restorative approach for tissue reconstruction based on a platform of biomorphic, biodegradable and programmable polymers. The project supports investments in R&D, clinical development, regulatory approvals and related product development and validation activities in order to reach market access and commercialisation of new products in Europe and the US.

E&S Risk Categorisation:	Low risk
Invest EU sustainability proofing required	Yes
Project included in Carbon Footprint Exercise ² :	No

Environmental and Social Assessment

The project concerns investments in research and development for which no significant impact on the environment is expected. Significant social benefits for health are expected.

Environmental Assessment

The Promoter is a French medical technology company that is specialised in developing new polymers and related accessories for surgical use. The project supports investments in research and development activities to be carried out in existing facilities without changing their already authorised scope, which includes all required environmental permits. The research and development activities of the project do not fall under either Annex I or Annex II of the EU Directive 2011/92/EU as amended by the 2014/52/EU Directive and therefore not subject to an Environmental Impact Assessment procedure.

Climate Assessment

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20 000 tonnes CO2e/year absolute (gross) or 20 000 tonnes CO2e/year relative (net) – both increases and savings.

Climate change mitigation:

The project has been assessed for Paris alignment and is considered to be aligned with both low-carbon and resilience goals as per the policies set out in the Climate Bank Roadmap and/or associated guidance and other relevant documents (e.g. the Energy Lending Policy).

Paris Alignment of projects:

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector, and it is not considered as a highly-vulnerable counterpart.

Social Assessment

The Promoter's facilities and practices comply with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices, especially with regard to labour standards and occupational health and safety. The Company's practices confirm with Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. The Company is an SME that produces medical products and devices and must comply with relevant medical device regulation (Regulation(EU) 2017/745) in Europe and in other regions where they intend to market their products.

Significant health benefits are expected due to better patient outcomes from the use of the Company's products.

Other Environmental and Social Aspects

Through the R&D activities and investments, the project will support the Promoter to create additional highly-skilled jobs, while positively contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Promoter has effective environmental and social policies and operating procedures in place, which are in line with industry standards. The project concerns investments in research and development for which no significant impact on the environment is expected with considerable social benefits expected.

Considering the above, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.

Sustainability proofing conclusion: The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.